Comparative Pharmacology
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDOMETRIN versus NORETHINDRONE ACETATE.
ENDOMETRIN vs NORETHINDRONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial thinning. Also binds to progesterone receptors, exerting antiestrogenic effects.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
Oral, 5 mg once daily for 14 days per cycle, beginning on day 1 of menstrual cycle; for endometriosis, 5 mg daily for 14 days then 10 mg daily for 14 days, then 15 mg daily, or as tolerated up to 15 mg daily continuous.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Terminal elimination half-life is approximately 5-8 hours (mean 7.5 hours). Clinically, steady-state is achieved within 2-3 days of daily dosing.
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Renal (39-61% as metabolites), biliary/fecal (35-49% as metabolites). Less than 1% excreted unchanged.
Category C
Category D/X
Progestin
Progestin